PhD Scientific Days 2023

Clinical Medicine - Posters J

Radiofrequency Ablation Treatment of Papillary Thyroid Microcarcinoma in Hungary

Előadó neve

Dr. Gyulay, Kata K

Neptun code

MLZQPE

Előadó munkahelye

Semmelweis University, Heart and Vascular Centre, Dept. of Interventional Radiology and Premier G Med Cardio Kft.

Előadó telefonszáma

+36206663066

Előadó e-mail címe

gyulay.kata@phd.semmelweis.hu

Az előadás címe

Radiofrequency Ablation Treatment of Papillary Thyroid Microcarcinoma in Hungary

Szerző(k) neve és munkahelye

Kata K Gyulay1,2, Ádám Z Farkas1,2, Pál Ákos Deák1,2
1 Semmelweis University, Heart and Vascular Centre, Department of Interventional Radiology
2 Premier G Med Cardio Kft.

Bemutatás módja

Poszter

Szekció

Clinical Medicine - Posters J

Language of the presentation

English

Preferred session

Clinical Medicine

Összefoglaló szövege

Introduction
Ultrasound-guided thermoablation has become a widely used treatment for benign thyroid nodules and low-risk papillary thyroid microcarcinomas (PTMCs), providing an alternative for patients who are not eligible for surgery or prefer not to undergo open surgery or active surveillance. This poster presents our interim results two years after the start of our project.
Aims
We aimed to perform radiofrequency ablation (RFA) of PTMCs among the first in Central and Eastern Europe, gathering further evidence on the safety and efficacy of the treatment in a Caucasian population.
Methods
Until 1 May 2023, we treated 23 patients with cytologically confirmed PTMC without cytological aggressiveness, extrathyroidal spread, lymph node, or distant metastases, using ultrasound-guided RFA under local anesthesia following hydrodissection. Tumor treatment was performed after informed consent and a supporting tumor board decision. Follow-up exams included laboratory tests, ultrasound, contrast-enhanced ultrasound (CEUS), and fine-needle aspiration biopsy. We measured the tumor volume pre-treatment and the volume of the ablation zone post-treatment. We analyzed our data using Wilcoxon signed-rank tests.
Results
The median original tumor volume was 132 mm3 (n=23). The median ablation volume measured 832 mm3 (n=20) during the 1-month control and showed intensive reduction during the follow-up: 320 mm3 at 3 months (n=19), 75 mm3 at 6 months (n=17), and 31 mm3 at 12 months (n=11). The volume of the ablation zone at 6 months did not show a significant difference from the original tumor size (p=0.73). The volume of the ablation zone continued to decrease at 12 months compared to 6 months, although the reduction was not statistically significant (p=0.09). Follow-up exams showed no contrast enhancement or washout, lymph node metastasis, or tumor recurrence. Common post-ablation complications were not present
Conclusion
Our results are similar to those found in the literature. They confirm the safety and effectiveness of RFA in treating low-risk PTMC.
Funding
The project (2020-1.1.2-PIACI-KFI-2020-00046) was funded and conducted by Premier G Med Cardio Kft. with the support of the Ministry of Innovation and Technology of Hungary from the NRDI Fund (2020-1.1.2-PIACI-KFI).

University and Doctoral School

Semmelweis University, Doctoral School of Theoretical and Translational Medicine

Supervisor

Ákos Pál Deák M.D., Ph.D., Prof. Zoltán Benyó M.D., Ph.D., D.Sc.

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

7515

Start

10:30

End

10:35

Authors (legacy)

Kata K Gyulay1,2, Ádám Z Farkas1,2, Pál Ákos Deák1,2
1 Semmelweis University, Heart and Vascular Centre, Department of Interventional Radiology
2 Premier G Med Cardio Kft.